NLRC4 and metabolic dysfunction-associated steatohepatitis: Importantly, NLRC4 inflammasome activation has been involved in several metabolic diseases such as colitis‐associated tumorigenesis [16], obesity‐associated breast cancer progression, non‐alcoholic steatohepatitis (NASH), diabetic nephropathy (DN) and type 1 diabetes (T1D).